Daiichi Sankyo Begins PIII Primary Dose Study for mRNA COVID Jab

September 2, 2022
Daiichi Sankyo said on September 1 that the first patient has been dosed in a Japanese PIII study for DS-5670, an mRNA vaccine against COVID-19, which aims to investigate its benefits for primary inoculations in healthy unvaccinated adults. In the...read more